Medicine and industry: A necessary but conflicted relationship

Perspectives in Biology and Medicine

Volumn 50, Issue 1, 2007, Pages 1-6

  Fisher, Morris A ^a  

^a HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT; COST; DEVICE; DRUG INDUSTRY; DRUG UTILIZATION; ECONOMIC ASPECT; EQUIPMENT; HEALTH CARE; MEDICAL CARE; MEDICAL PRACTICE; PHYSICIAN; PRIORITY JOURNAL; PROFIT; REVIEW; UNITED STATES;

EID: 33846622359     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2007.0003     Document Type: Review

References (19)

1. Abelson, R., and S. Saul. 2005. Ties of industry cloud a clinic's mission. NY Times, Dec. 17.
2. Abraham, J. 1995. Science, politics, and the pharmaceutical industry: Controversy and bias in drug regulation. New York: St. Martin's.
3. Berenson, A. 2006. Cancer drug's big price rise disturbs doctors and patients. NY Times, March 12.
4. CDRH Consumer Information. 2002. http://www.fda.gov/cdrh/consumer/ geninfo. html.
5. Consumers International. 2006. Branding the cure. http://www. consumersinternational. org/pharma.
6. Drum, K. 2004. Political animal. Washington Monthly, July 14.
7. Fisher, M. A. 2003. Physicians and the pharmaceutical industry: A dysfunctional relationship. Perspect Biol Med 46:254-72.
8. Fisher, M. A., and S. Glass. 1997. Butorphanol (Stadol): A study in the problems of current drug information and control. Neurology 48:1156-60.
9. Fontanarosa, P. B., D. Rennie, and C. D. DeAngelis. 2004. Postmarketing surveillance: Lack of vigilance, lack of trust. JAMA 292:2647-50.
10. Fortune 500. 2006. http://money.cnn.com/magazines/fortune/fortune500/ full_list/.
11. Hall, S. S. 2001. Prescription for profit. NY Times Mag, March 11.
12. Harris, G. 2006. FDA guidelines of limits experts' ties to drug makers. NY Times, July 25.
13. Heffler, S., et al. 2004. Health spending projections through 2013. Health Aff W4:79-93.
14. Kerber, R. 2005. FDA halts expansion of network to monitor medical device safety. Boston Globe, July 14.
15. Lawson, G. W. 2005. Impact of use fees (i.e. drug industry money) on changes within the FDA. PhD diss., Univ. of LaVerne School of Public Administration, http://www.fda study.com/.
16. Lurie, P, et al. 2006. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration drug advisory committee meetings. JAMA 295:1921-28.
17. Mansfield, P. R., B. Mintzes, and D. Richards. 2005. Direct to consumer advertising. BMJ 330:5-6.
18. Pear, R. 2004. Health spending rises to 15% of economy, a record level. NY Times, Jan. 9.
19. Relman, A. S. 1980.The new medical-industrial complex. N Engl J Med 303:963-70.